Slide 1: Q1 2024 Results Presentation
Q1 2024 Results Presentation Dietmar Siemssen, CEO Dr. Bernd Metzner, CFO Düsseldorf, April 11, 2024
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Highlights Q1 2024
Highlights Q1 2024 Dietmar Siemssen (CEO)
Slide 4: Strategic Partner of Choice for the Global Pharma and Biotech Industry
Strategic Partner of Choice for the Global Pharma and Biotech Industry Digital Therapy Containment Support Solutions Improve patient’s health outcome Bring the drug to the patient Drug Delivery Systems Bring the drug into the patient 4 11-Apr-2024 Gerresheimer AG - Q1 2024 Results Presentation
Slide 5: Strategy for Sustainable Profitable Growth and Value Creation
Strategy for Sustainable Profitable Growth and Value Creation Q1 2024: Further Margin Expansion – Overall Performance as Expected Organic Development: − P&D driving Revenue growth: Adj. EBITDA growth: continued profitable − Ramping up for strong +2.8% +5.9% growth H2 2024 Adj. EPS growth: − Strong c
Slide 6: Accelerate Execute Innovate
Leveraging on Unique Business Opportunities to Drive Long-Term Growth Key Priorities in FY 2024 Accelerate sustainable, profitable growth by consistently increasing the revenue share of systems and solutions for biologics and injectables Accelerate — Execute ongoing growth projects and operational e
Slide 7: Strong Path for Further Sustainable Profitable Growth
Strong Path for Further Sustainable Profitable Growth Key Contributors to Growth CAGR ≥ +10% Revenue 2023 Solid Base Growth High-value Solutions Medical Devices Mid-Term Revenue Biologics Unique and broad systems and solutions portfolio providing high value to customers and sustainable long-term gro
Slide 8: Overview of our Ongoing Growth Projects
Overview of our Ongoing Growth Projects Execution According to Plan USA Morganton | Peachtree City Germany Pfreimd North Macedonia Skopje Czech Republic Horšovský Týn Mexico Querétaro China Zhenjiang 8 11-Apr-2024 Gerresheimer AG - Q1 2024 Results Presentation
Slide 9: Current State of Expansion Projects
Current State of Expansion Projects Ramp-up of first new lines starting in 2024 Peachtree, USA Morganton, USA Horšovský Týn, Czech Republic Querétaro, Mexico Skopje, North Macedonia Zhenjiang, China 9 11-Apr-2024 Gerresheimer AG - Q1 2024 Results Presentation
Slide 10: Solid Start into FY 2024
Solid Start into FY 2024 Dr. Bernd Metzner (CFO)
Slide 11: Q1 2024: Solid Start into the Year
Q1 2024: Solid Start into the Year Operational View on KPIs in Q1 2024 Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) Organic growth yoy: Organic growth yoy: Organic growth yoy: +2.8% +5.9% -3.0% 466 81 0.71 458 78 0.65 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 11 11-Apr-2024 Ger
Slide 12: P&D driving Margin Expansion
P&D driving Margin Expansion Operational View on KPIs in Q1 2024 by Division Organic yoy In EUR m & margin Revenues Adj. EBITDA +13.7% +27.3% 258 59 Strong Organic Growth and Margin Improvement 229 47 22.8% ▪ Organic revenue growth of 13.7% especially driven by strong demand P&D 20.4% for medical de
Slide 13: Reconciliation Q1 2024
Reconciliation Q1 2024 Reported and Adjusted Financials Q1 2024 Q1 2023 Org. growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 466.1 466.1 457.8 2.8% EBITDA 78.3 2.6 80.9 78.0 5.9% Depreciation & Amortization -46.4 9.7 -36.7 -34.1 EBIT 31.9 12.3 44.2 43.9 Financial Result
Slide 14: Good Cash Flow from Operating Activities
Good Cash Flow from Operating Activities Cash Flow and Net Financial Debt In EUR m Q1 2024 Q1 2023 Change Adjusted EBITDA 80.9 78.0 2.9 Change in net working capital -24.3 -91.7 67.4 Net interest paid -6.2 -5.7 -0.6 Net taxes paid -6.2 -7.4 1.2 Other -17.0 -22.3 5.3 Cash flow from operating activiti
Slide 15: Outlook
Outlook Dietmar Siemssen (CEO)
Slide 16: Accelerate Execute Innovate
Leveraging on Unique Business Opportunities to Drive Long-Term Growth Key Priorities in FY 2024 — Accelerate sustainable, profitable growth by consistently increasing the revenue share of biologics and injectables Accelerate — Execute ongoing growth projects and operational excellence Execute — Furt
Slide 17: Guidance
Guidance FY 2024, FY 2025 and Mid-Term Guidance Revenue Adjusted Adjusted EPS Growth EBITDA Growth FY 2024 5-10% 430-450 8-12% EUR m FY 2025 10-15% ≥ 22% ≥ 10% Margin Mid-term ≥ 10% 23-25% ≥ 10% CAGR Margin CAGR 17 11-Apr-2024 Gerresheimer AG - Q1 2024 Results Presentation
Slide 18: Appendix
oO £ (a) o£ Q OL
Slide 19: Financial Calendar
Financial Calendar Publication 4th Quarter/ Full-year 2024 Results Publication 3rd Quarter 2024 Results Publication Half-year 2024 Results Virtual Annual General Meeting 2024 February 26th, 2025 October 10th, 2024 July 11th, 2024 June 5th, 2024 19 11-Apr-2024 Gerresheimer AG - Q1 2024 Results Presen
Slide 20: Q1 Revenue & Organic Growth Reconciliation
Q1 Revenue & Organic Growth Reconciliation (1 of 2) in EUR m organic growth +2.8% -16.2 31.1 465.4 0.7 466.1 -2.8 0.7 -7.2% 457.8 -5.1 452.7 +13.7% Revenue Q1 2023 FX Revenue Q1 P&D PPG GAT HQ, Cons. Revenue Q1 FX Revenue Q1 2024 2023 (organic) 2024 (organic) 20 11-Apr-2024 Gerresheimer AG - Q1 2024
Slide 21: Q1 Adj. EBITDA & Organic Growth Reconciliation
Q1 Adj. EBITDA & Organic Growth Reconciliation (2 of 2) in EUR m organic growth margin +5.9% -4.5 -2.2 12.6 -11.4% -1.4 80.6 0.3 80.9 78.0 -1.9 +17.3% 76.1 16,8% +27.3% Adj. EBITDA FX Adj. EBITDA Q1 P&D PPG GAT HQ, Cons. Adj. EBITDA Q1 FX Adj. EBITDA Q1 2023 2023 (organic) 2024 (organic) Q1 2024 21
Slide 22: Solid Financial Foundation
Solid Financial Foundation Net Financial Debt & Adjusted EBITDA Leverage Net Financial Debt according to credit agreement in force Maturity Profile In EUR m In EUR m Q1 2024 Q1 2023 Promissory loans Revolving credit facilities (RCF, total volume) Revolving credit facilities1 230 291 792 942 200 Prom
Slide 23: innovating for a better life
innovating for a better life